Ratings Alembic Pharmaceuticals Limited

Equities

APLLTD

INE901L01018

Delayed NSE India S.E. Other stock markets 02:41:07 2024-04-30 EDT			5-day change	1st Jan Change
998 ^INR	+0.12%		+6.14%	+31.42%

04-26	Alembic Pharmaceuticals Limited Receives Order from the Office of Deputy Commissioner (ST), Guwahati, Assam	CI
04-18	Alembic Pharmaceuticals Board to Consider Dividend for Fiscal 2024; Shares Drop 3%	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 32.99 times its estimated earnings per share for the ongoing year.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The valuation of the company is particularly high given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
The three month average target prices set by analysts do not offer high potential in comparison with the current prices.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
ALEMBIC PHARMACEUTICALS LIMITED	+31.42%	2.35B	C+
ELI LILLY AND COMPANY	+26.47%	664B	C+
NOVO NORDISK A/S	+26.74%	567B	B
JOHNSON & JOHNSON	-6.33%	354B	C+
MERCK & CO., INC.	+19.35%	330B	B-
ABBVIE INC.	+4.23%	286B	C+
ASTRAZENECA PLC	+13.43%	234B	B+
NOVARTIS AG	+4.71%	199B	B-
ROCHE HOLDING AG	-9.53%	196B	A+
AMGEN INC.	-4.04%	148B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes